Table 1.
Characteristics of women with diagnosed breast cancer by race/ethnicity, 2007–2009
| Non-Hispanic White N (%) | Non-Hispanic Black N (%) | Hispanic N (%) | Asian N (%) | |
|---|---|---|---|---|
| Total | 12,178 (81.1) | 1,085 (7.2) | 923 (6.1) | 716 (4.8) |
| Age (years) | ||||
| 65–69 | 3,206 (26.3) | 292 (26.9) | 295 (32.1) | 199 (27.8) |
| 70–74 | 2,805 (23.0) | 273 (25.2) | 228 (24.7) | 172 (24.0) |
| 75–79 | 2,520 (20.7) | 224 (20.7) | 183 (19.8) | 172 (24.0) |
| ≥80 | 3,647 (30.0) | 296 (27.3) | 217 (23.5) | 173 (24.2) |
| Marital status | ||||
| Married | 5,023 (41.3) | 185 (17.1) | 314 (24.0) | 254 (49.4) |
| Unmarried | 6,722 (55.2) | 848 (78.2) | 575 (62.3) | 348 (48.6) |
| Unknown | 433 (3.6) | 52 (4.8) | 34 (3.7) | 14 (2.0) |
| SES (% living below FPL) | ||||
| 1st tertile (<5.4) | 4,322 (35.5) | 109 (10.1) | 146 (15.8) | 215 (30.0) |
| 2nd tertile (5.4–11.8) | 4,251 (34.9) | 203 (18.7) | 216 (23.4) | 253 (35.3) |
| 3rd tertile (>11.8) | 3,605 (29.6) | 773 (71.2) | 561 (60.8) | 248 (34.6) |
| SEER Registry Region | ||||
| Northeast | 2,554 (21.0) | 229 (21.1) | 151 (16.4) | 50 (7.0) |
| South | 3,168 (26.0) | 528 (48.7) | <4% | <3% |
| Midwest | 1,580 (13.0) | 109 (10.1) | <2% | <2% |
| West | 4,876 (40.0) | 219 (20.2) | 726 (78.7) | 635 (88.7) |
| Metropolitan area (yes) | 9,625 (79.0) | 917 (84.5) | 845 (91.6) | 685 (95.7) |
| Comorbidity scores | ||||
| 0 | 6,992 (57.4) | 411 (37.9) | 448 (48.5) | 360 (50.3) |
| 1 | 3,082 (25.3) | 299 (27.6) | 266 (28.8) | 235 (32.8) |
| 2 | 1204 (9.9) | 168 (15.5) | 110 (11.9) | 75 (10.5) |
| 3+ | 900 (7.4) | 207 (19.1) | 99 (10.7) | 46 (6.4) |
| Year of diagnosis | ||||
| 2007 | 3,956 (32.5) | 363 (33.5) | 295 (32.0) | 230 (32.1) |
| 2008 | 4,043 (33.2) | 354 (32.6) | 310 (33.6) | 237 (33.1) |
| 2009 | 4,176 (34.3) | 368 (33.9) | 318 (34.5) | 249 (34.8) |
| Tumor size (cm) | ||||
| <2.0 | 7,519 (61.7) | 483 (44.5) | 466 (50.5) | 410 (57.3) |
| ≥2.0 | 4,623 (38.0) | <56% | <49% | <43% |
| Unknown | 36 (0.3) | <2% | <2% | <2% |
| Number of positive nodes | ||||
| 0 | 7,906 (64.9) | 565 (52.1) | 547 (59.3) | 460 (64.3) |
| ≥1 | 2,768 (22.7) | 331 (30.5) | 270 (29.3) | 183 (25.6) |
| Unknown | 1,504 (12.4) | 189 (17.4) | 106 (11.5) | 73 (10.2) |
| Tumor grade | ||||
| Well differentiated | 3,178 (26.1) | 168 (15.5) | 186 (20.2) | 173 (24.2) |
| Moderately differentiated | 5,445 (44.7) | 428 (39.5) | 402 (43.6) | 305 (42.6) |
| Poorly differentiated | 2,956 (24.3) | 413 (38.1) | 282 (30.6) | 206 (28.8) |
| Unknown | 599 (4.9) | 76 (7.0) | 53 (5.7) | 32 (4.5) |
| Surgery treatment | ||||
| None | 294 (2.4) | 73 (6.7) | 32 (3.5) | 16 (2.2) |
| BCS | 7,216 (59.3) | 512 (47.2) | 505 (54.7) | 368 (51.4) |
| Mastectomy | 4,668 (38.3) | 500 (46.1) | 386 (41.8) | 332 (46.4) |
| Chemotherapy (yes) | 2,849 (23.4) | 332 (30.6) | 310 (33.6) | 204 (28.5) |
| Radiation therapy (yes) | 6,864 (56.4) | 515 (47.5) | 537 (58.2) | 380 (53.1) |
| Hormone receptor status | ||||
| ER+ or PR+ | 10,111 (83.0) | 780 (71.9) | 716 (77.6) | 577 (80.6) |
| ER− and PR− | 1,507 (12.4) | 234 (21.6) | 144 (15.6) | 101 (14.1) |
| Unknown | 560 (4.6) | 71 (6.5) | 63 (6.83) | 38 (5.3) |
| AJCC Stage | ||||
| I | 7,038 (57.8) | 454 (41.8) | 445 (48.2) | 386 (53.9) |
| II | 4,010 (32.9) | 463 (42.7) | 337 (36.5) | 248 (34.6) |
| III | 1,130 (9.3) | 168 (15.5) | 141 (15.3) | 82 (11.5) |
BCS, breast conservation therapy; ER, estrogen receptor; PR, progesterone receptor.
*Actual percentages were not reported to avoid N<11 reporting, as required by the data user agreement.